Skip to main content
Journal cover image

Completeness of required site-specific factors for brain and CNS tumors in the Surveillance, Epidemiology and End Results (SEER) 18 database (2004-2012, varying).

Publication ,  Journal Article
Ostrom, QT; Gittleman, H; Kruchko, C; Louis, DN; Brat, DJ; Gilbert, MR; Petkov, VI; Barnholtz-Sloan, JS
Published in: J Neurooncol
October 2016

Cancer registries are an important source of population-level information on brain tumor incidence and survival. Surveillance, Epidemiology, and End Results (SEER) registries currently collect data on specific required factors related to brain tumors as defined by the American Joint Commission on Cancer, including World Health Organization (WHO) grade, MGMT methylation and 1p/19q codeletion status. We assessed 'completeness', defined as having valid values over the time periods that they have been collected, overall, by year, histology, and registry. Data were obtained through a SEER custom data request for four factors related to brain tumors for the years 2004-2012 (3/4 factors were collected only from 2010 to 2012). SEER*Stat was used to generate frequencies of 'completeness' for each factor overall, and by year, histology and registry. The four factors varied in completeness, but increased over time. WHO grade has been collected the longest, and showed significant increases in completeness. Completeness of MGMT and 1p/19q codeletion was highest for glioma subtypes for which testing is recommended by clinical practice guidelines. Completeness of all factors varied by histology and cancer registry. Overall, several of the factors had high completeness, and all increased in completeness over time. With increasing focus on 'precision medicine' and the incorporation of molecular parameters into the 2016 WHO CNS tumor classification, it is critical that the data are complete, and factors collected at the population level are fully integrated into cancer reporting. It is critical that cancer registries continue to collect established and emerging prognostic and predictive factors.

Duke Scholars

Altmetric Attention Stats
Dimensions Citation Stats

Published In

J Neurooncol

DOI

EISSN

1573-7373

Publication Date

October 2016

Volume

130

Issue

1

Start / End Page

31 / 42

Location

United States

Related Subject Headings

  • United States
  • Tumor Suppressor Proteins
  • SEER Program
  • Retrospective Studies
  • Registries
  • Public Health Surveillance
  • Prognosis
  • Oncology & Carcinogenesis
  • Male
  • Incidence
 

Citation

APA
Chicago
ICMJE
MLA
NLM
Ostrom, Q. T., Gittleman, H., Kruchko, C., Louis, D. N., Brat, D. J., Gilbert, M. R., … Barnholtz-Sloan, J. S. (2016). Completeness of required site-specific factors for brain and CNS tumors in the Surveillance, Epidemiology and End Results (SEER) 18 database (2004-2012, varying). J Neurooncol, 130(1), 31–42. https://doi.org/10.1007/s11060-016-2217-7
Ostrom, Quinn T., Haley Gittleman, Carol Kruchko, David N. Louis, Daniel J. Brat, Mark R. Gilbert, Valentina I. Petkov, and Jill S. Barnholtz-Sloan. “Completeness of required site-specific factors for brain and CNS tumors in the Surveillance, Epidemiology and End Results (SEER) 18 database (2004-2012, varying).J Neurooncol 130, no. 1 (October 2016): 31–42. https://doi.org/10.1007/s11060-016-2217-7.
Ostrom QT, Gittleman H, Kruchko C, Louis DN, Brat DJ, Gilbert MR, et al. Completeness of required site-specific factors for brain and CNS tumors in the Surveillance, Epidemiology and End Results (SEER) 18 database (2004-2012, varying). J Neurooncol. 2016 Oct;130(1):31–42.
Ostrom, Quinn T., et al. “Completeness of required site-specific factors for brain and CNS tumors in the Surveillance, Epidemiology and End Results (SEER) 18 database (2004-2012, varying).J Neurooncol, vol. 130, no. 1, Oct. 2016, pp. 31–42. Pubmed, doi:10.1007/s11060-016-2217-7.
Ostrom QT, Gittleman H, Kruchko C, Louis DN, Brat DJ, Gilbert MR, Petkov VI, Barnholtz-Sloan JS. Completeness of required site-specific factors for brain and CNS tumors in the Surveillance, Epidemiology and End Results (SEER) 18 database (2004-2012, varying). J Neurooncol. 2016 Oct;130(1):31–42.
Journal cover image

Published In

J Neurooncol

DOI

EISSN

1573-7373

Publication Date

October 2016

Volume

130

Issue

1

Start / End Page

31 / 42

Location

United States

Related Subject Headings

  • United States
  • Tumor Suppressor Proteins
  • SEER Program
  • Retrospective Studies
  • Registries
  • Public Health Surveillance
  • Prognosis
  • Oncology & Carcinogenesis
  • Male
  • Incidence